# Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

> **NCT00995085** · PHASE1 · COMPLETED · sponsor: **Alcobra Ltd.** · enrollment: 43 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Extended Release Metadoxine

## Key facts

- **NCT ID:** NCT00995085
- **Lead sponsor:** Alcobra Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2017-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00995085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00995085, "Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00995085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*